Just Now, Pfizer's Blockbuster Small Molecule New Drug Paxlovid was Urgently Approved in China!

On February 11, the Chinese Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the "Drug Administration Law" and in accordance with the special drug approval procedures, and approved Pfizer's new covid treatment drug Nirmatrelvir Tablets/Ritonavir Tablets with conditions of combination packaging (as Paxlovid) import registration.

This product is an oral small-molecule novel coronavirus treatment drug for the treatment of adults with mild to moderate novel coronavirus pneumonia (COVID-19) with high risk factors for progression to severe disease, such as advanced age, chronic kidney disease, diabetes, patients with severe high-risk factors such as cardiovascular disease and chronic lung disease.  

Patients should strictly follow the instructions for medication under the guidance of physicians, and should pay close attention to the interaction information with other drugs listed in the instructions during use.

The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner.